Taletrectinib

Rami Manochakian: Zongertinib in Previously Treated HER2-Mutant NSCLC

Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared an article on X:

Just published in NEJM. Results of: Beamion LUNG-1 phase 1a–1b of: Zongertinib (Oral, irreversible, HER2 TKI) in previously treated Patients with advanced HER2-mutant non-small- cell Lung Cancer (NSCLC).

“Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer”

Authors: John V. Heymach et al.

Rami Manochakian

 

 

Behbood Sadrolhefazi Byoung Chul Cho cancer David Planchard Egbert F. Smit Ernest Nadal Gerrina Ruiter Hai-Yan Tu John V. Heymach Jon Zugazagoitia Joshua K. Sabari Kiyotaka Yoh Maren Rohrbacher Myung-Ju Ahn NEJM Nicolas Girard Noboru Yamamoto NSCLC OncoDaily Oncology Sabina Eigenbrod-Giese Ute von Wangenheim Yanqiu Zhao Yi-Long Wu